10+ Mesothelioma Journal Background. Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum. We conducted a phase iii trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone.
Current Concepts in the Evaluation and Treatment of ... from jnccn.org Most tumors arise from the pleura, and so this article will focus on pleural mesothelioma. The exact prevalence is unknown but it is estimated that mesotheliomas represent less than 1% of all cancers. The diagnosis of peritoneal and pleural mesothelioma is often delayed, due to a long latent period between onset and symptoms and the common and nonspecific clinical presentation.
Cancer incidence and mortality among petroleum industry workers and.
Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. Mesothelioma research plays a crucial role in developing new and effective treatments for the cancer. Although an mpm diagnosis can be reliable on cytology, the reported sensitivity is low (30% to 75%). Mesothelioma, also known as malignant mesothelioma, is an aggressive malignant tumor of the mesothelium.
No comments:
Post a Comment